Categories Earnings, Finance

Wells Fargo beats on revenues, misses on earnings in Q3

Banking giant Wells Fargo (NYSE: WFC) on Tuesday reported revenues of $22 billion for the third quarter of 2019, which exceed the street consensus of $21.2 billion.

Meanwhile, Q3 earnings of 92 cents per share missed the average analysts’ estimate of $1.14 per share. The bank pointed out that the EPS for the quarter included discrete litigation accrual of 35 cents and a gain of 20 cents from the sale of its Institutional Retirement and Trust unit.

wells fargo wfc q3 2019 earnings results. wells fargo reported mixed bag

Without these two one-time items, Q3 EPS would still have missed the estimate by 7 cents.

WFC shares were slightly down during pre-market trading hours on Tuesday. The stock has gained a modest 4% from the beginning of this year.

CFO John Shrewsberry said, “Our net charge-off rate remained near historic lows, and we had strong capital returns, including increasing our quarterly common stock dividend by 19% and reducing our common shares outstanding by 9% compared with a year ago, while maintaining a strong capital position.”

Last month, Wells Fargo had announced the appointment of Charles W. Scharf as the new Chief Executive Officer and President, effective October 21. Scharf was previously Chairman and CEO at Bank of New York Mellon.

Meanwhile, rival Citigroup Inc. (NYSE: C) reported a 6% increase in earnings for the third quarter of 2019 helped by the lower effective tax rate and higher revenues despite higher expenses and cost of credit. The results exceeded analysts’ expectations.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top